L 735882
Latest Information Update: 08 Jun 2001
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Antivirals
- Mechanism of Action DNA-directed RNA polymerase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 08 Jun 2001 No-Development-Reported for Influenza virus infections in USA (Unknown route)
- 01 Feb 1995 Preclinical development for Influenza virus infections in USA (Unknown route)